Perjeta/Phesgo conversion is now at 47% ... In regards to your question around the Lilly molecule and our CT-996 that structure has not yet been disclosed. And I think as we sort of repeatedly ...

but probably the margin means that we want to take a slightly more conservative capital structure stance, maybe keeping a bit more cash than we might otherwise and maybe not fully using all of the ...

Roche’s Herceptin and Perjeta duo is already part of a well-established standard of care in early-stage HER2-positive breast cancer. Now, the company can further back up the regimen’s prowess ...

The APHINITY study confirmed significant overall survival benefits of a Perjeta-based regimen in HER2-positive early-stage breast cancer, especially for lymph node-positive patients. Ten-year data ...

Long term follow-up in this curative setting demonstrated clinically meaningful survival benefit when adding adjuvant Perjeta® (pertuzumab) to Herceptin® (trastuzumab) and chemotherapy1 21% reduction ...

Long term follow-up in this curative setting demonstrated clinically meaningful survival benefit when adding adjuvant Perjeta ® (pertuzumab) to Herceptin ® (trastuzumab) and chemotherapy ...

Ten-Year APHINITY Data Show Genentech’s Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer – Long term follow-up in this curative setting ...

Roche’s Perjeta (pertuzumab)-based regimen has demonstrated sustained survival benefits in patients with early-stage breast cancer, according to new results from a long-term study of the drug. The ...

Long term follow-up in this curative setting demonstrated clinically meaningful survival benefit when adding adjuvant Perjeta® (pertuzumab) to Herceptin® (trastuzumab) and ...

91.6% of patients on Perjeta-based therapy are alive at 10 years vs. 89.8% with the standard regimen. 21% reduced death risk in node-positive subgroup, confirms prior invasive disease-free ...

After ten years, the risk of death was reduced by 17% for people treated with Perjeta (pertuzumab), Herceptin (trastuzumab) and chemotherapy (the Perjeta-based regimen) for a year as post-surgery ...